<DOC>
	<DOCNO>NCT01929317</DOCNO>
	<brief_summary>This study Phase III , multicentre , randomize , initial double-blind study subsequent open label phase . The study havea screen phase ( 4 week ) , dose increase effect verification phase ( 12 week ) , titration 1 phase ( 1 week ) , long-term phase ( 39 week ) , titration 2 phase ( 1 2 week ) follow phase . Subjects assign Ropinirole CR high-dose group Ropinirole CR maintenance group ratio 3:1 . This study conduct evaluate efficacy ( effect increase Ropinirole dose 16 mg/day 18-24 mg/day ) Ropinirole CR tablets early advanced PD patient achieve optimal therapeutic response market Ropinirole Immediate release ( IR ) ( 15 mg/day ) market Ropinirole CR ( 16 mg/day ) formulation .</brief_summary>
	<brief_title>A Study Evaluate Efficacy 18 24mg/Day Ropinirole Controlled Release ( CR ) Tablets Early Advanced Parkinson 's Disease ( PD ) Patients .</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Inclusion criterion start screen Patients diagnose Parkinson 's Disease severity modify Hoehn &amp; Yahr criterion Stages IIV . 1 ) Monotherapy subject : Subjects never receive Ldopa , subject prior exposure Ldopa ( 450 milligram ( mg ) /day ) 3 month total Ldopa treatment discontinue , minimum 4 week prior screen phase . 2 ) Ldopa adjunct subject : Subjects receive Ldopa ( 450 mg/day ) least 4 week prior screen phase . Patients receive 15mg/day Ropinirole IR 16mg/day Ropinirole CR 4 week prior screen phase , UPDRS Part III total ( ) score 10 point screen visit expect clinical efficacy increase Ropinirole CR . Age : 20years old ( time inform write consent ) Informed consent : Patients able give inform write consent person . ( i.e . patient capable give informed write consent ) Sex : Either sex . Women childbearing potential eligible inclusion study . However negative pregnancy test screen visit agree pregnancy test time point determine study assessment procedure practice one method contraception mention protocol screen visit end followup examination Outpatient status correct QT ( QTc ) &lt; 450 millisecond ( msec ) &lt; 480msec subject Bundle Branch Block . The QTc base single average QTc value triplicate electrocardiogram ( ECGs ) obtain brief recording period . Liver function test : Patients aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2x upper limit normal ( ULN ) ; Alkaline Phosphatase bilirubin = &lt; 1.5xULN ( isolated bilirubin &gt; 1.5ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) screen visit . Randomization Criteria Patients whose UPDRS Part III total ( ) score 10 point week 0 Patients achieve optimal therapeutic response treatment 16mg/day Ropinirole CR require high dose Ropinirole CR Patients 80 % compliant take study drug Exclusion Criteria Late stage advance patient demonstrate incapacitate peak dose biphasic dyskinsia stable dose Ldopa . Patients used dopamine agonist ( except Ropinirole IR CR ) within 4 week prior screen phase . Patients treat follow drug 4 week earlier start screen phase , whose treatment regimen drug change . Anticholinergic agent : trihexyphenidyl hydrochloride , piroheptine hydrochloride , mazaticol hydrochloride , metixene hydrochloride , biperiden hydrochloride , profenamine , amantadine hydrochloride , droxidopa , citicoline , selegiline hydrochloride , entacapone , zonisamide , Estrogens , CYP1A2 inhibitor . Patients change smoke habit ( start stop smoke ) within screen phase . Patients treat investigational drug within 12 week prior screen phase . Patients present serious physical sign symptom PD ( e.g . cardiac/hepatic/renal disorder haematopoietic disorder ) . Patients symptomatic postural hypotension . ( e.g . dizziness syncope ) . Patients current history drug abuse alcoholism . Patients severe dementia score 3 4 UPDRS item 1 ( Mentation , behaviour , mood ) . Patients current history major psychosis ( e.g . schizophrenia psychotic depression ) score 3 4 UPDRS item 2 ( think disorder ) item 3 ( depression ) . Patients receive surgical treatment PD past ( e.g . pallidectomy , deep brain stimulation ) . Female patient pregnant lactating , may pregnant , plan pregnancy study within 30 day last dose study drug . Unstable liver disease ( define presence ascites , encephalopathy , coagulapathy , hypoalbuminaemia , oesophageal gastric varix persistent jaundice ) , cirrhosis , know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Chronic hepatitis B administer immunosuppressive agent due risk hapatitis B reactivation . Patients history drug allergy Ropinirole hydrochloride . Except patient history basal cell carcinoma , patient current history cancer malignant tumor within 5 year prior screen phase . Others investigator ( subinvestigator ) considers ineligible study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Ropinirole</keyword>
	<keyword>Parkinson 's disease</keyword>
</DOC>